Correlation Between Atreca and Passage Bio
Can any of the company-specific risk be diversified away by investing in both Atreca and Passage Bio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Atreca and Passage Bio into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Atreca Inc and Passage Bio, you can compare the effects of market volatilities on Atreca and Passage Bio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Atreca with a short position of Passage Bio. Check out your portfolio center. Please also check ongoing floating volatility patterns of Atreca and Passage Bio.
Diversification Opportunities for Atreca and Passage Bio
-0.16 | Correlation Coefficient |
Good diversification
The 3 months correlation between Atreca and Passage is -0.16. Overlapping area represents the amount of risk that can be diversified away by holding Atreca Inc and Passage Bio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Passage Bio and Atreca is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Atreca Inc are associated (or correlated) with Passage Bio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Passage Bio has no effect on the direction of Atreca i.e., Atreca and Passage Bio go up and down completely randomly.
Pair Corralation between Atreca and Passage Bio
If you would invest 70.00 in Passage Bio on August 30, 2024 and sell it today you would lose (3.34) from holding Passage Bio or give up 4.77% of portfolio value over 90 days.
Time Period | 3 Months [change] |
Direction | Moves Against |
Strength | Insignificant |
Accuracy | 1.59% |
Values | Daily Returns |
Atreca Inc vs. Passage Bio
Performance |
Timeline |
Atreca Inc |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Passage Bio |
Atreca and Passage Bio Volatility Contrast
Predicted Return Density |
Returns |
Pair Trading with Atreca and Passage Bio
The main advantage of trading using opposite Atreca and Passage Bio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Atreca position performs unexpectedly, Passage Bio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Passage Bio will offset losses from the drop in Passage Bio's long position.Atreca vs. Passage Bio | Atreca vs. Stoke Therapeutics | Atreca vs. Revolution Medicines | Atreca vs. Black Diamond Therapeutics |
Passage Bio vs. Ikena Oncology | Passage Bio vs. Eliem Therapeutics | Passage Bio vs. HCW Biologics | Passage Bio vs. RenovoRx |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Stock Screener module to find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook..
Other Complementary Tools
Money Managers Screen money managers from public funds and ETFs managed around the world | |
AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years |